Locations and Appointments
Please contact the doctor's office to verify that your insurance is accepted.
- Blue Access
- Blue Connection
- Mediblue (Senior)
- Medicare Advantage
- Community Plan
About Justin Kaner, MD
Dating back to my time in undergrad, I have been cultivating an interest in hematologic malignancies. I have always found acute leukemias in particular to be fascinating due to their aggressive behavior and rapid response to therapy. In AML, there have been recent FDA-approvals to increase the number of therapies available to patients, but there remains a great need for developing novel therapeutics. Participating in this research to investigate and develop new treatment prospects is exciting to me. During fellowship, under the mentorship of Drs. Roboz and Guzman, I had the opportunity to work on the development of a clinical trial protocol for relapsed/refractory AML which has further propelled my interest in early phase clinical trials and drug development. I will continue to pursue these research endeavors as I begin my full-time faculty career at Weill Cornell.
I’m also passionate about providing compassionate care to people with blood cancers. I am proud to be part of a multidisciplinary team providing care for our patients, including social workers, nurses, PAs/NPs, and other faculty and researchers within the Weill Cornell Leukemia Program. I will primarily be taking care of hospitalized leukemia patients and hope to focus on improving their experience in the hospital through novel research approaches and initiatives, while providing the best care possible.
Dr. Justin Kaner graduated with a B.S. in Biology from Syracuse University in 2009 where his initial interest in hematologic malignancies developed. He received his M.D. from New York Medical College in 2013 before completing his Internal Medicine Residency at Albert Einstein College of Medicine/Montefiore Medical Center. During residency Dr. Kaner pursued his interest in hematologic malignancies by undertaking several research projects mainly focused on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) which led to several publications in peer reviewed journals, including Leukemia and Lymphoma and Oncotarget, as well as numerous abstracts presented at the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) Annual Meetings. Additionally, Dr. Kaner served as Chief Resident after his residency at Montefiore Medical Center.
Throughout his Hematology/Oncology fellowship at Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Kaner worked in the laboratory of Dr. Monica Guzman and with clinical mentorship from Dr. Ellen Ritchie and Dr. Gail Roboz of the Weill Cornell Leukemia Program. During this time, he studied the activity of a novel therapeutic, PU-H71, in PTPN11 mutated AML as well as the prognostic impact of PTPN11 mutations in AML. During his fellowship training Dr. Kaner also developed a particular interest in early phase clinical trials and novel therapeutics for the treatment of Relapsed/Refractory AML. Dr. Kaner accepted an opportunity to remain at Weill Cornell, joining the Leukemia Program to focus on caring for hospitalized patients with various acute and chronic leukemias, MDS and myeloproliferative neoplasms (MPNs).
M.D.New York Medical College2013
Assistant Attending PhysicianNewYork-Presbyterian Hospital
Assistant Professor of Clinical MedicineWeill Cornell Medical College, Cornell University
Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.
No External Relationships Reported